Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

  • Unknown sort schema '{last_sort_schema}' ignored
  • The following term was not found in PubMed: D%5BAuthor%5D.
1.

Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells.

Bach AS, Derocq D, Laurent-Matha V, Montcourrier P, Sebti S, Orsetti B, Theillet C, Gongora C, Pattingre S, Ibing E, Roger P, Linares LK, Reinheckel T, Meurice G, Kaiser FJ, Gespach C, Liaudet-Coopman E.

Oncotarget. 2015 Sep 29;6(29):28084-103. doi: 10.18632/oncotarget.4394.

2.

Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment.

Laurent-Matha V, Huesgen PF, Masson O, Derocq D, Prébois C, Gary-Bobo M, Lecaille F, Rebière B, Meurice G, Oréar C, Hollingsworth RE, Abrahamson M, Lalmanach G, Overall CM, Liaudet-Coopman E.

FASEB J. 2012 Dec;26(12):5172-81. doi: 10.1096/fj.12-205229. Epub 2012 Aug 16.

3.

Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1-regulated intramembrane proteolysis.

Derocq D, Prébois C, Beaujouin M, Laurent-Matha V, Pattingre S, Smith GK, Liaudet-Coopman E.

Oncogene. 2012 Jun 28;31(26):3202-12. doi: 10.1038/onc.2011.501. Epub 2011 Nov 14.

4.

Cathepsin-D, a key protease in breast cancer, is up-regulated in obese mouse and human adipose tissue, and controls adipogenesis.

Masson O, Prébois C, Derocq D, Meulle A, Dray C, Daviaud D, Quilliot D, Valet P, Muller C, Liaudet-Coopman E.

PLoS One. 2011 Feb 2;6(2):e16452. doi: 10.1371/journal.pone.0016452.

5.

Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth.

Beaujouin M, Prébois C, Derocq D, Laurent-Matha V, Masson O, Pattingre S, Coopman P, Bettache N, Grossfield J, Hollingsworth RE, Zhang H, Yao Z, Hyman BT, van der Geer P, Smith GK, Liaudet-Coopman E.

J Cell Sci. 2010 Oct 1;123(Pt 19):3336-46. doi: 10.1242/jcs.070938. Epub 2010 Sep 7.

6.

Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity?

Masson O, Bach AS, Derocq D, Prébois C, Laurent-Matha V, Pattingre S, Liaudet-Coopman E.

Biochimie. 2010 Nov;92(11):1635-43. doi: 10.1016/j.biochi.2010.05.009. Epub 2010 May 21. Review.

7.

Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells.

Nirdé P, Derocq D, Maynadier M, Chambon M, Basile I, Gary-Bobo M, Garcia M.

Oncogene. 2010 Jan 7;29(1):117-27. doi: 10.1038/onc.2009.311. Epub 2009 Oct 5.

8.

Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B.

Laurent-Matha V, Derocq D, Prébois C, Katunuma N, Liaudet-Coopman E.

J Biochem. 2006 Mar;139(3):363-71.

9.

Transcriptional regulation of the human NRIP1/RIP140 gene by estrogen is modulated by dioxin signalling.

Augereau P, Badia E, Fuentes M, Rabenoelina F, Corniou M, Derocq D, Balaguer P, Cavailles V.

Mol Pharmacol. 2006 Apr;69(4):1338-46. Epub 2006 Jan 3.

10.

Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis.

Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M, Glondu-Lassis M, Laurent-Matha V, Prébois C, Rochefort H, Vignon F.

Cancer Lett. 2006 Jun 18;237(2):167-79. Epub 2005 Jul 19. Review.

PMID:
16046058
11.

Sigma receptor ligands: applications in inflammation and oncology.

Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P.

Curr Opin Investig Drugs. 2004 Nov;5(11):1158-63. Review.

PMID:
15573866
12.

Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells.

Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M.

Oncogene. 2002 Aug 1;21(33):5127-34.

14.
15.

Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation.

Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A, Bouaboula M, Galiègue S, Mondière P, Pénarier G, Fur GL, Defrance T, Casellas P.

Blood. 1998 Nov 15;92(10):3605-15.

16.

Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview.

Rochefort H, Platet N, Hayashido Y, Derocq D, Lucas A, Cunat S, Garcia M.

J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):163-8. Review.

PMID:
9699869
17.

The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.

Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Ségui M, Casellas P.

FEBS Lett. 1998 Apr 3;425(3):419-25.

18.
19.

SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC, Le Fur GL.

J Pharmacol Exp Ther. 1998 Feb;284(2):644-50.

20.

Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor.

Garcia M, Derocq D, Platet N, Bonnet S, Brouillet JP, Touitou I, Rochefort H.

J Steroid Biochem Mol Biol. 1997 Apr;61(1-2):11-7.

PMID:
9328205

Supplemental Content

Loading ...
Support Center